Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.00.
Several research analysts have recently commented on the company. HC Wainwright lowered their target price on Nkarta from $22.00 to $18.00 and set a "buy" rating for the company in a research note on Monday, November 11th. Mizuho lowered their price objective on Nkarta from $20.00 to $16.00 and set an "outperform" rating for the company in a research report on Thursday, November 21st. Rodman & Renshaw started coverage on shares of Nkarta in a research note on Wednesday, October 9th. They issued a "buy" rating and a $14.00 target price on the stock. Needham & Company LLC dropped their price target on shares of Nkarta from $13.00 to $11.00 and set a "buy" rating for the company in a research report on Friday, November 8th. Finally, RODMAN&RENSHAW upgraded shares of Nkarta to a "strong-buy" rating in a research report on Wednesday, October 9th.
Get Our Latest Research Report on NKTX
Institutional Investors Weigh In On Nkarta
Several hedge funds have recently made changes to their positions in NKTX. Meeder Asset Management Inc. bought a new stake in shares of Nkarta in the 2nd quarter worth approximately $26,000. GAMMA Investing LLC grew its stake in shares of Nkarta by 1,887.0% in the second quarter. GAMMA Investing LLC now owns 4,729 shares of the company's stock worth $28,000 after acquiring an additional 4,491 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Nkarta during the third quarter valued at $33,000. Forefront Analytics LLC purchased a new position in shares of Nkarta in the 2nd quarter worth about $70,000. Finally, Intech Investment Management LLC bought a new position in Nkarta in the 3rd quarter worth about $74,000. 80.54% of the stock is currently owned by institutional investors.
Nkarta Stock Up 14.6 %
Shares of Nkarta stock traded up $0.38 during trading on Thursday, reaching $2.99. The company's stock had a trading volume of 1,848,032 shares, compared to its average volume of 1,155,259. The company has a market cap of $211.00 million, a price-to-earnings ratio of -1.59 and a beta of 0.86. The firm's 50-day moving average is $3.63 and its two-hundred day moving average is $5.17. Nkarta has a 52-week low of $2.38 and a 52-week high of $16.24.
About Nkarta
(
Get Free ReportNkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Featured Articles
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
